Dow Chemical has spun off its biotech arm Pfenex, which specializes in strain engineering and protein production. Dow, however, will maintain a minority stake in Pfenex along with Signet Healthcare Partners. Dow's investments in the company have already boosted the potential of Pfenex for "significant growth" as an independent company, said Ken Van Heel, global director of Dow Venture Capital.

Related Summaries